Nigeria to expand therapy to 100,000 AIDS patients

	Tweet

Nigeria will dramatically increase the number of AIDS sufferers receiving life-saving drugs this year after its cash-strapped AIDS programme received a financial boost, the country’s health minister said.

Nigeria, Africa’s most populous nation, launched the programme in 2002 to provide antiretroviral (ARV) drugs from India to 10,000 adults and 5,000 children at a subsidised monthly cost of 1,000 naira ($7) per patient.

But financial problems mean that only 14,000 of about 3.5 million sufferers are receiving the ARVs at the government’s 25 HIV/AIDS treatment centres.

“Council today decided that we should scale-up the treatment ... to 100,000 HIV-positive patients this year,” Health Minister Eyitayo Lambo told reporters late on Wednesday after a regular cabinet meeting in the capital Abuja.

Lambo said some of the cash to expand the programme would come from the global AIDS fund, which is providing $20 million over three years, and the World Health Organisation (WHO).

Nigeria said last year it was looking to the United States and international donor agencies to provide $248 million to expand ARV therapy to 200,000 sufferers, after its AIDS programme suffered an acute shortage of ARVs. 

RELATED STORIES:
U.S. OKs wrinkle-filler for HIV patients   Gilead, Merck, Bristol-Myers to combine HIV drugs   HIV vaccine trial begins in February 2005   India to begin trials of HIV vaccine on humans   Mobile phones keep track of HIV treatments   Beijing to Install Condom Machines to Fight AIDS   Malawi losing 10 people per hour to AIDS   China’s cabinet orders urgent measures to curb AIDS   China Approves Testing for Potential AIDS Vaccine   U.S. fights criticism at AIDS conference   HIV testing advised for all sexually active people   HIV treatment: 2 million years of life saved

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]